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1. Introduction
1.1. The genesis and evolution of acrylic bone cement
1.1.1. History
Otto Röhm is known as the developer of polymethylmethacrylate (PMMA) in 1901. Industri‐
al-size chemical synthesis of MMA was achieved in the 1920s in the laboratories of Rohm
and Haas, and the first biomedical applications of PMMA was the fabrication of dentures. In
the 1930s it was discovered that the mixing of MMA monomer and benzoyl peroxide initia‐
tor with prepolymerized PMMA powder resulted in the formation of a dough-like material
which could slowly harden into a glassy polymer. This two-component polymer (cement)
was initially used to close cranial defects. Because of the transparency, strength, and stabili‐
ty of polymethylmethacrylate, the commercial production of cast sheets of it in the early
1930s led to its utilization as a denture base and prosthetic material. Originally pieces of the
material were molded under heat and pressure.[1, 2, 3] In 1935, an injection molding techni‐
que was introduced by ICI for dentures in which the melted PMMA was injected into dried
plaster molds under hydraulic pressure. These techniques proved to be too cumbersome. In
1936, as was mentioned above, it was discovered that mixing of methyl methacrylate mono‐
mer with the ground polymer produced a dough that could be shaped in plaster molds and
could be polymerized into a solid mass by using benzoyl peroxide as a polymerization ini‐
tiator. In the next few years, it was found that improved molding characteristics could be
obtained using a powder that was a mixture of ground and spherical (bead) polymer parti‐
cles.[1, 2]
© 2013 Hosseinzadeh et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The discovery of the dough molding technique led to the near universal use of these acrylic
resins for dentures and prostheses for cranioplasties in the 1940s.[4] In 1943, German chem‐
ists discovered that if a tertiary amine such as dimethyl-pare-toluidine was added along
with the benzoyl peroxide, the dough could be polymerized at room temperature. Based on
this development, Kulzer and Degussa companies refined a dough-like, workable form of
PMMA in 1943. Their developments led to the introduction of cold-cured PMMA, which
hardens at room temperature. In the 1940s, with the advent of acrylic femoral hemiarthro‐
plasties by Jean and Robert Judet, PMMA attracted interest in the field of orthopaedics. Kia‐
er and Haboush separately reported using PMMA to affix femoral implants in the early
1950s. The success with and the popularity of PMMA in orthopaedics is attributable to Sir
John Charnley, whose work was affected by his exposure to the field of dentistry (because
his father was a dentist) and his inherent interest in biomaterials. Charnley’s early clinical
accomplishments established a foundation for the continued use of PMMA in orthopaedics.
Charnley had a long experience in producing his own instruments and gadgets. Charnley
was interested in the work on thin sectioning of bones and rocks embedded in cast acrylic
resin. He also performed a research into Judet prostheses and acrylic joints cast in alginate
molds. He performed some arthroplasties with acrylic bone cement and reported the pre‐
liminary results of six cases in the British Journal of Bone and Joint Surgery in 1960. It is im‐
portant to appreciate that this advance was not simply the use of acrylic cement but rather a
conscious recognition of its ability to fill completely the medullary canal and adapt to the
bone interface, so facilitating stress transfer, minimizing local stresses, and thereby stabiliz‐
ing and anchoring the prosthesis. It was a new technique and provided the basis for the de‐
velopment of Charnley’s concept of low friction arthroplasty during the next decade.[1, 2]
For over 40 years, poly(methylmethacrylate) (PMMA)-based bone cement, commonly
known as acrylic bone cement, has been used for fixation of total joint replacement prosthe‐
ses to periprosthetic bone. Today, most acrylic bone cements on the market consist of two
components: a liquid and a powder one, which are mixed in the operating room until they
become dough-like and are then applied to the bone prior to insertion of the component of
the joint replacement prosthesis. The primary function of cements is to fix the joint replace‐
ment prosthesis to the periprosthetic bone tissue.[5] The basic component of acrylic bone ce‐
ments is methylmethacrylate (MMA), which is an ester of methacrylic acid. In 1951, Kaier
and Jansen in Copenhagen were the first to use PMMA bone cement for the fixation of acryl‐
ic cups to the subchondral bone of the femoral head. In 1953, Haboush used bone cement as
a seating material for femoral head replacements without inserting it into the medullary ca‐
nal. In 1958, Sir John Charnley used acrylic bone cement to fix femoral prostheses in the fe‐
mur, as is done in modern-day joint arthroplasty these days. Charnley used a self-curing
PMMA cement called Nu-Life, which was a pink-colored denture repair material. These ear‐
ly total hip replacements had a high incidence of failure, and it was not because of the ce‐
ment or stems but because of the use of polytetrafluoroethylene (PTFE) acetabular cups. In
1966, CMW began to supply the first sterilized bone cement, formulated specifically for fixa‐
tion of total joint replacement prostheses.[5] Nowadays, uncemented total hip replacement
prostheses designs have largely been introduced in the orthopedic market, but acrylic ce‐
ments continue to be one of the best primary methods of fixation of joint replacement pros‐
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theses, especially for knee replacement prostheses. In addition, injectable formulations of
acrylic bone cements have been used for applications in vertebroplasty.
Several factors such as their chemical composition, viscosity, porosity, radiopacifiers and an‐
tibiotic additives, mixing methods, sterilization, temperature during handling, mechanical
properties, and biocompatibility, affect the clinical performance of bone cements.
2. Composition and chemistry
The methylmethacrylate monomer consists of two carbon atoms that are covalently bound,
with one of the carbon atoms covalently bonded to two hydrogen atoms and the other at‐
tached via a covalent bond to a methyl and acrylic group. Polymerization of MMA mono‐
mer produces PMMA, which is a polymer or a macromolecule. Hardened acrylic bone
cement consists of linear, uncross-linked PMMA macromolecules of various lengths ranging
from a few tens of thousands to a few million grams per mole. Acrylic bone cements com‐
prise two components, often supplied in a 2:1 ratio: (a) a powder component, usually in a 40
g package, and (b) a liquid component, in a 20 mL ampoule.[2, 6](Table 1) There are several
reasons for using a two-component bone cement instead of simply polymerizing pure MMA
monomer:
The polymerization of MMA monomer is too slow and can take several hours or days, de‐
pending on the type and amount of reaction initiator used.
Pure MMA monomer has a very low viscosity and can easily diffuse into the blood stream,
which can lead to cardiorespiratory and vascular complications.
The heat of polymerization can easily increase the temperature of the cement to over 100°C
(boiling point for MMA = 100.3°C), which could lead to boiling of the volatile MMA mono‐
mer. The use of less amount of monomer and the presence of prepolymerized PMMA beads
in the powder decreases the number of polymerization reaction and hence, the amount of
released heat and assists in heat dissipation, decreasing the overall temperature.
After polymerization of pure MMA into PMMA, there would be a volumetric shrinkage of
21% due to differences in the density of the MMA monomer and the PMMA polymer. This
amount of shrinkage is unacceptable and would lead to a large gap at the cement-bone and
cement-prosthesis interface, compromising the fixation of the prosthesis.
The powder is the variable part in composition of bone cements among different brands,
which contributes to differences in properties. (Figure 1) The powder component primarily
consists of prepolymerized PMMA beads of 10 to 150 µm diameter, contributing to 83% to
99% of the powder. The prepolymerized beads of different bone cements include copoly‐
mers of MMA with styrene, methyl acrylate, or butyl methacrylate comonomers. The re‐
maining components include a radiopacifier, either barium sulfate (BaSO4) or zirconium
dioxide (ZrO2) (8% to 15% by weight), as well as an initiator, benzoyl peroxide (0.75% to
2.6%). The MMA monomer can self-polymerize under exposure to heat and light, but, this
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reaction is very slow. Therefore, dibenzoyl peroxide (BPO) reaction initiator in powder form
is included in the powder component. Other variations include the initiator tri-n-butylbor‐
ane and accelerator 2,5-dimethylhexane- 2,5-hydroperoxide(in Bonemite, chlorophyll dye
and ethanol and ascorbic acid. The initiator, radiopacifier, and antibiotic powders all consist
of particles of approximately 1 µm in diameter. [7]
Constituent Role
Powder components
Polymer Polymethylmethacrylate
Co-polymer (e.g. MA-MMA) Alter physical properties of the cement
Barium sulphate or Zirconium dioxide Radio-opacifiers
Antibiotics* Antimicrobial prophylaxis
Dye (e.g. chlorophyll) Distinguish cement from bone
Liquid components
Monomer Methylmethacrylate monomer
N,N-dimethyl-p-toluidine (DMPT) Initiates cold curing of polymer
Benzoyl peroxide Reacts with DMPT to catalyze polymerization
Hydroquinone Stabilizer preventing premature polymerization
Dye (e.g. chlorophyll) Distinguish cement from bone
*Plain bone cements do not contain antibiotics
Table 1. Commercial constituents of bone cement
The monomer, a colorless liquid with a characteristic odor, is packaged in ampules. The liq‐
uid components remain relatively constant among commercially available cements. 97% to
99% of this liquid consists of methylmethacrylate. N,N-dimethyl-para-toluidine (DMPT)
makes up 0.4% to 2.8% by weight and acts as an accelerator to speed up the polymerization
and setting of the cement. Since MMA can spontaneously polymerize during storage, addi‐
tion of trace amounts of a stabilizer, usually hydroquinone (15 to 75 ppm), stabilizes and
prevents premature polymerization of monomers.
MMA polymerizes by the mechanism of free radical polymerization, which consists of three
steps: initiation, propagation, and termination. The initiation step involves decomposition of
BPO monomer into radicals at room temperature.[7] (Figure 2)
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Figure 1. The composition of the powder of several PMMA bone cements on the market.
Figure 2. The initiation of the polymerization of MMA: BPO from the powder and DMPT from the liquid react to form
radicals, starting the curing of bone cements.
Upon mixing of the two components, the DMPT in the liquid component decomposes BPO
into a benzoyl radical and a benzoate anion as follows:
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where BPO = (C6H5COO)2, DMPT= CH3C6H4N(CH3)2, benzoyl radical = C6H5COO*, and ben‐
zoate anion = C6H5COO-.
The second step of the free radical polymerization is chain propagation in which the benzoyl
radical reacts with the MMA monomer as follows:
6 5 2 3 3 6 5 2 3 3 2 3 3
6 5 2 3 3 2 3 3
C H COO* + CH =CCH COOCH  C H COO-CH -CCH COOCH + CH =CCH COOCH  
C H COO-CH CCH COOCH -CH CCH COOCH
¾¾® ¾¾® (2)
The free radical attacks one of the double bonds of the MMA monomer. One electron of
the double bond pairs up with the electron of the free radical to form a bond between the
oxygen of  the benzoyl free radical  and one of  the carbon atoms of  the MMA monomer
while the second electron of the double bond shifts to the other carbon atom, which then
turns into a free radical.  This free radical  then attacks another MMA monomer and the
chain  propagates  until  a  PMMA  of  relatively  high  molecular  weight,  on  the  order  of
100,000 to 1,000,000 g/mol, is achieved. Finally, chain termination can be achieved by chain
coupling as follows:
2 3 3 2 2 3 3 2-CH CXCH * + *CXCH CH -  -CH CXCH -CXCH CH -¾¾® (3)
or, to a lesser extent, by disproportionation via transfer of a hydrogen atom as follows:
2 3 3 2 2 X 2-CH CXCH * + *CXCH CH - -CH C CH + CXH=CH-¨¾¾® (4)
where X refers to the substituent COOCH3.
The glass transition temperature of PMMA is about 105OC, but the glass transition tempera‐
ture of hardened PMMA-based bone cement can be lower due to plasticization effects of re‐
sidual monomer and water. With proceeding of polymerization, the growing polymer
chains slowly turn into a hard, glassy material, and it becomes difficult for the monomer to
diffuse through the hardened PMMA matrix to continue chain propagation. [8]
The hardened acrylic bone cement consists primarily of linear, uncross-linked PMMA mac‐
romolecules of various lengths, but their length (or molecular weight) can vary widely. The
molecular weight of the hardened cement depends on several factors, such as (a) the molec‐
ular weight of the monomer used (usually MMA), (b) the molecular weight of the prepoly‐
merized beads, (c) the ratio of the initiator and the accelerator, (d) the presence of stabilizers,
(e) the ambient temperature during polymerization, and (f) the sterilization method.[7, 8]
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3. Properties
3.1. Heat production during polymerization
Combining powder and liquid monomer initiates an exothermic reaction. In vitro, the peak
temperatures reach 113°C. In vivo temperatures are reported to be between 40° and 56°C.
Methylmethacrylate monomer, the basic building block of PMMA, contains carbon-carbon
double bonds, which react with the free radical produced by the activator and initiator. The
monomer free radical interacts with other monomer molecules, creating a growing polymer
chain. During the polymerization, the powder changes to a workable dough. [7]
This reaction releases 52 KJ/mole of monomer, equating to heat production of 1.4 to 1.7 × 108
J/m3 of cement. The production of heat by the curing cement has been studied in vitro and in
vivo and modeled using finite element analysis. In vitro studies have shown that the thicker
cement mantles, the higher ambient temperatures and the greater ratio of monomer to poly‐
mer the more heat is produced. Recorded temperatures range between 70°C and 120°C. Col‐
lagen denatures with prolonged exposure to temperatures in excess of 56°C, and the risk of
causing thermal damage to bone has been emphasized by several authors. However, in vivo
studies have recorded lower peaks of temperature. In 1977, Reckling and Dillon measured
the temperature at the bone cement interface in 20 THRs. The maximum temperature was
48°C.[9] The reasons for the lower in vivo temperature are:
1. The thin layer of the bone cement
2. Blood circulation
3. The large surface area of the interface
4. Poor thermal conductivity of the cement
5. Heat dissipation to the prosthesis and to the vital tissue.
So, the temperature increase greater than the coagulation temperature of proteins is avoid‐
ed.
Harving, Soballe and Bunger recorded temperatures above 56°C but only for two to three
minutes. Even though, such temperatures may sometimes be reached, animal studies have
shown no adverse effects. Nevertheless, concerns regarding thermal and chemical injury
persisted.[3]
3.2. Curing of a bone cement
By mixing the powder and liquid, two different processes are started. First, the polymer
powder takes up the monomer liquid, forming a more or less viscous fluid or a dough. This
phenomenon is because of the swelling and dissolution processes of monomer and polymer
powder. Swelling and dissolution processes are physical processes and they are important
for the working characteristics of a bone cement. Second, a chemical process is initiated,
which is responsible for the final hardening of the bone cement. The initiator BPO from the
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polymer powder and the activator DMPT from the liquid interact to produce free radicals in
the so-called ‘‘initiation reaction’’. These radicals are able to start the polymerization of
MMA by adding to the polymerizable double-bond of the monomer molecule. This results
in a growing polymer chain that builds up macromolecules. Because of the high number of
radicals generated, many rapidly growing polymer chains are formed and, therefore, there
is a fast conversion of MMA to PMMA. If two growing polymer chains meet, the chains are
terminated by combining both, resulting in an unreactive polymer molecule. The polymeri‐
zation of MMA is an exothermic reaction, resulting in a temperature increase in the curing
bone cement.[7] This temperature maximum can be influenced by:
1. The chemical composition of the cement
2. By the powder to liquid ratio
3. By the radiopacifier.
3.3. Volume shrinkage
Because a polymerization means a conversion of a large number of monomer molecules to a
much smaller number of polymer molecules, there is a volume shrinkage during curing of
the bone cement. The reason for this shrinkage is the decreasing molecular distance between
free monomer molecules before the polymerization and the molecular distance of the mole‐
cules bonded in the polymer chain. The volume shrinkage of pure MMA is approximately
21%. By using prepolymerized powder, the content of MMA in commercially available bone
cements is reduced to approximately one third of the whole mass. The theoretic volume
shrinkage of bone cements is therefore approximately 6%–7%. The real shrinkage is lower,
however, because of the air inclusions in the cement dough. So, the real volume shrinkage of
hand-mixed bone cement thus might be lower than the shrinkage of vacuum-mixed bone ce‐
ment, because vacuum-mixed cement has hardly any air inclusions. Because acrylic bone ce‐
ment absorbs water, its volume shrinkage is compensated by the expansion caused by the
water-uptake.[8]
4. Processing and handling of bone cement
The handling characteristics and setting times of acrylic cements are of great importance for
orthopedic surgeons. The handling of bone cements can be described by four different phas‐
es with their corresponding viscosities:
1. The mixing phase (up to 1 minute) is the period during which the powder and the liq‐
uid are homogenized thoroughly. The powder and the liquid can be mixed manually by
using a bowl and a spatula or by a special mixing system, applying vacuum to avoid
the formation of voids.
2. The waiting phase (up to several minutes, according to the type of cement and the han‐
dling temperature) is the period to reach a non-sticky state of the cement.
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3. The working phase (2–4 minutes, according to the type of cement and the handling tem‐
perature) is the period during which the surgeon can inject the cement and insert the
prosthesis. The viscosity of the cement has to be high enough to withstand the bleeding
pressure. Blood pervasion of the cement results in a reduction of the strength of the ce‐
ment. A late application at a too high viscosity level may result in poor interfaces be‐
tween the prosthesis, the cement, and the bone.
4. The hardening phase (1–2 minutes) is the period of the final setting process and the de‐
velopment of the polymerization heat.
The effect of the temperature on the length of the phases is clearly visible. The information giv‐
en by the temperature versus time curves of different cements is not always comparable, be‐
cause manufacturers use different determination methods resulting in variant lengths of the
working phases. This disagreement is caused by the lack of a universal detection method. A
wide experience and knowledge by the surgeon is therefore helpful to find the optimal range
of time to inject the cement and to fix the prosthesis. The method described in ISO 5833 and
ASTM F 451 to determine a viscosity-like parameter is the intrusion test. This is not really a test
method for the determination of the true viscosity. To perform this test, the mixed cement is
placed in a plastic mold and is loaded with a force of 49 N for 1 minute. The depth of the intru‐
sion of the cement into four drill holes is measured. This method is only available for high vis‐
cosity bone cements. In the standard ASTM F 451, there is another extrusion viscosity test
described with a capillary rheometer for low viscosity bone cements. [7]
In the Standards, there are two further time parameters defined: the doughing time and the
setting time. The doughing time end by the beginning of the working phase and it is deter‐
mined by recording from the start time of mixing until the mixture is able to separate clean‐
ly from a gloved finger. The second time parameter is the setting time, which is defined as
the time to reach a temperature midway between ambient and maximum. The end of setting
time marks the final hardening of the bone cement. [8]
During the waiting period swelling of the beads occurs and allows the polymerization to
proceed, leading to an increase in viscosity. At this stage, the cement turns into a sticky
dough. The working period begins when the cement is no longer sticky but of sufficiently
low viscosity to permit the surgeon to easily apply the cement into the prepared place. Dur‐
ing this period, the chain propagation continues, along with an increase in viscosity. The vis‐
cosity of the cement must be carefully assessed before inserting the cement because with a
very low viscosity the cement would not be able to withstand the bleeding pressure. This
would result in blood lamination in the cement, which can weaken the cement. The heat
produced during this period, results in thermal expansion of the cement. On the other hand,
there is a volumetric shrinkage of the cement as the MMA monomer converts into the dens‐
er PMMA polymer.
The final stage is the hardening period, when the polymerization terminates and leads to a
hardened cement. The temperature of the cement continues to elevate during this period
and then slowly decreases to body temperatures. During this period, the cement undergos
volumetric shrinkage along with thermal shrinkage as the cement cools down to body tem‐
perature. While the manufacturer can determine the hardening period length using in vitro
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measurements at a controlled temperature and humidity in a laboratory environment, it is
difficult to predict the hardening period in vivo, with accuracy due to variations in the am‐
bient environment in the operating room, the body temperature, and thickness of the ce‐
ment mantle, all of which can alter the setting times of the cement. Several factors, such as
the type of mixing method used, the viscosity of the cement, the precooling of the monomer
and/or powder, the preheating of the powder component, and the preheating of the prosthe‐
sis, can also significantly alter the times of some of the handling phases. Thus it is important
for the surgeon to know each of the factors that can alter the duration of each phase. [7]
4.1. Viscosity and handling properties
The dynamic viscosity (η) of fluids is denoted by shear stress (F)/shear rate (S) [η = F/S]. Flu‐
ids are designated as Newtonian if shear stress is linearly related to shear rate. Cement in its
liquid phase of curing behaves as a non-Newtonian fluid with viscosity decreasing as shear
rate is increased. This is called pseudoplastic or shear thinning behaviour. However, the vis‐
cosity of all cements increases during polymerisation as the polymer chains lengthen.[10]
The mixed cement begins as a viscous liquid, then turns into a viscoelastic material, and fi‐
nally hardens into a predominantly elastic solid. Thus, it is important to monitor both the
dynamic viscosity as well as the viscoelastic parameters, such as storage modulus (G'), loss
modulus (G"), and tanδ (their ratio). A high storage modulus indicates that the material is
more solid-like whereas a high loss modulus shows that the material is more viscous.[7]
The viscosity of bone cements at the dough stage is determined mainly by the chemical compo‐
sition and the powder to monomer ratio. These aspects should never be modified in the operat‐
ing theater to modify the viscosity. There are some methods to modify the viscosity without
changing other characteristics of the cement, however. One of them is the prechilling of the ce‐
ment. The velocity of the reaction, and with it the viscosity, depends on the temperature. Pre‐
chilling  of  cements,  especially  of  high  viscosity  cements,  has  been  introduced  with  the
introduction of mixing systems to make mixing of cement in these systems more convenient
and to improve the quality of the mixture, especially with respect to porosity. [8]
Another method for applying this change is preheating the cement, to accelerate the poly‐
merization and thus, reducing the operation time. But it has been shown that by this heat
application to the cement powder, various characteristics of the cement itself or the cement‐
ed construct are either enhanced, degraded, or marginally affected, which depends on the
structure of the cement powder and its stability against the heat. Specifically, these proper‐
ties are significantly decreased when the principal constituent in the powder has a low re‐
sistance to degradation by the preheat temperature (as is the case of the PMMA polymer in
Cemex XL and CMW 1 cements) but are not when the resistance is high (as in the case of a
mixture of PMMA + MMA styrene copolymer in Surgical Simplex P cement).[11]
Manufacturers can also change the viscosity of cement by changing the molecular weight,
by using co-polymers, and by varying the methods of sterilization. In addition, the curing
process itself can be controlled by altering the proportions of the initiator (Toluidine) and
the monomer, and this can change the working properties.
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The cement must be liquid enough during the working phase to be forced through a deliv‐
ery device and then flow under pressure to penetrate the interstices of cancellous bone, ach‐
ieving micro-interlock. Bone cements are usually divided into three categories: high,
medium and low viscosity:
Low. These have a long waiting phase of three minutes, also known as a sticky phase. The
viscosity rapidly increases during the working phase and the hardening phase is one to two
minutes long.
Medium. There is a long waiting phase of three minutes, but during the working phase, the
viscosity only increases slowly. Hardening takes between one minute 30 seconds, and two
minutes 30 seconds.
High. A short waiting/sticky phase is followed by a long working phase. The viscosity re‐
mains constant until the end of the working phase. The hardening phase lasts between one
minute 30 seconds and two minutes. High viscosity cements are therefore forgiving for the
surgeon and are in predominant use in orthopaedics. [3]
However, the rates of curing are very sensitive to environmental factors. Low ambient tem‐
peratures during storing and mixing, and high humidity both prolong setting time. Typical
representatives of high viscosity cements are Palacos R (Biomet Inc.; Warsaw/USA; Scher‐
ing-Plough; Heist-op-den-Berg/Belgium; Heraeus Kulzer; Wehrheim/Germany), Palamed
(Biomet Merck; Ried/Switzerland; Heraeus Kulzer), CMW 1 (DePuy; Blackpool/England),
Simplex P (Stryker; Limerick/Ireland), and Cemfix 1 (Teknimed; Vic en Bigorre/France),
whereas Osteopal (Biomet Merck; Heraeus Kulzer), Palacos LV (Schering-Plough; Heraeus
Kulzer), Osteobond (Zimmer; Warsaw/USA), Versabond (Smith & Nephew; Memphis/
USA), Cemfix 3 (Teknimed), Sulcem 3 (Zimmer; Baar/Switzerland), and CMW 3 (DePuy) are
examples of low viscosity cements. [7]
The high viscosity during mixing might be a disadvantage, because this supports the entrap‐
ping of air. The viscosity is the most important handling property for the surgeon and deter‐
mines the working properties of the cement.
4.2. Residual monomer and monomer release
Radical polymerization of the MMA in bone cement generally does not proceed to comple‐
tion, because the mobility of remaining monomer molecules is inhibited at high conversion
rates. There will remain, therefore, some residual monomer. Directly after curing, the content
of residual monomer is approximately 2%–6%. In the following 3 weeks this content decreases
to approximately 0.5%. The main part (approximately 80%) of the total residual monomer is
post-polymerized slowly. A smaller part of the residual monomer is released from the cement
and metabolized to carbon dioxide and water in the citric acid cycle.(Figure 3) In earlier times,
released MMA was considered the main reason for perioperative respiration and circulation
upset. However, these effects are definitely the result of the increase in the intramedullary
pressure and fat embolism. They are not caused by the residual monomer. [7]
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Figure 3. Residual monomer in acrylic bone cement: post-polymerization and release with subsequent degradation.
4.3. Radiopacity
After a total joint replacement, if the cement does not have a distinct opacity, the surgeon can‐
not monitor the healing process clearly. This is the reason why radiopaque materials are add‐
ed to bone cements, so the hardened cement is radiopaque. Barium sulfate or zirconium
dioxide is used as opacifiers in all available bone cements.(Figure 4) The radiopacifier does not
contribute to the polymer chain. It is dispersed uniformly in the polymer powder and in the re‐
sulting solid bone cement. Animal experiments and in vivo studies with different cell cultures
showed more osteolytic changes by using barium sulfate than by using zirconium dioxide. De‐
spite the low solubility of barium sulfate, toxic barium ions can be released. On the other hand,
the abrasive properties of zirconium dioxide seem to be a disadvantage. All bone cements ex‐
amined contain 8.0%–15.0% opacifier within the polymer. Zirconium dioxide provides higher
opacity to bone cements compared to barium sulfate. Bone cements with more than 15.0% zir‐
conium dioxide in the polymer have the most distinct opacity.[2, 3, 7]
4.4. Molecular weight and sterilization
The molecular weight of the polymer powder particles is affected strongly by the steriliza‐
tion procedure used. Sterilization by γ-irradiation or β-irradiation significantly lowers the
molecular weight, whereas sterilization by ethylene oxide has no influence on the molecular
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weight of the polymer. The molecular weight influences the swelling properties and the me‐
chanical properties of the bone cement; therefore, low molecular weights have a few disad‐
vantages. Sterilization by ethylene oxide is the preferred method for bone cements, because
there is no change in material properties during sterilization. [12]
Figure 4. Content of radiopaquer in the powder of several acrylic bone cements; two radiopaquer agents are used in
commercial products: Barium sulfate and Zirconium dioxide.
5. Cement morphology
The composition of hardened cement consists of prepolymerized beads of PMMA or their
copolymers fused with the polymerized MMA monomer, in addition to radiopacifiers and
additives, such as powders of antibiotics, as well as pores or voids and residual initiator.
These parts of a cement composition act as flaws. These flaws can be due to: (a) air dissolved
within the powder particles; (b) air entrapment during mixing of powder and liquid mono‐
mer; (c) incomplete fusion of prepolymerized PMMA beads with the setting MMA; (d)
evaporation of the volatile monomer due to the heat of reaction during setting; (e) air en‐
trapment during transfer of the dough to the gun; and (f) air entrapment during introduc‐
tion of cement into the medullary canal. The major problem associated with the presence of
flaws is that when a critical flaw size is achieved, the flaws act as sites of stress concentra‐
tion, leading to weakening of the cement. But if the critical flaw size is not reached, they act
as crack blunting part of the cement upon its fracture. In other words, the cracks deviate
from their path when they encounter flaws in their path associated with pores and radiopa‐
cifier particles. The Griffith crack criterion assumes that there exists a critical flaw size
unique to each material above which its fracture strength is compromised. For PMMA, the
critical flaw size is 70 µm. Thus, if the pores are smaller than the critical flaw size for
PMMA, the porosity will not compromise the fracture strength of bone cement. It is general‐
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ly well known that hardened bone cement contain macropores (pore diameter greater than 1
mm) and micropores (pore diameter 0.01-1.0 mm). Based on the Griffith theory, elimination
of the macropores would be more important than elimination of the micropores, especially
the pores much smaller than 70 µm in diameter. The most common method of eliminating
pores is to use centrifugation and vacuum mixing methods. Another source of flaws that can
be potential sites of high stress concentration is radiopacifier powder particles. A radiopaci‐
fier powder, usually barium sulfate or zirconium oxide, consists of particles with a broad
range of sizes, from approximately 0.2 to 2 µm in diameter. Zirconium oxide is a harder ma‐
terial than barium sulfate. Thus, if there is loosening, there could be concerns with regards
to third body abrasive wear in the bearing surface of the joint replacement. Barium sulfate is
generally insoluble, but there are concerns about toxicity of barium ions. Poor spread of ra‐
diopacifier particles in the region between the prepolymerized cement beads can affect both
crack initiation and crack propagation, especially if they are larger than the critical flaw size
for PMMA. The radiopacifier particles do not bond with PMMA and instead reside within
pores, which are larger than these particles due to cement shrinkage. [13, 8]
6. Mixing techniques and its effect on porosity
Mixing techniques are of great importance in determining the content and size of flaws that
can affect the cement toughness. Historically, three methods of mixing of cement have been
employed: (a) hand mixing in air; (b) hand mixing followed by centrifugation; and (c) hand
mixing in an evacuated mixing device, commonly known as "vacuum mixing." [8, 14]
Hand mixing involves mixing of the liquid and powder components in an open bowl using
a spatula at a speed of 1 to 2 Hz for a period of duration of approximately 2 minutes. The
hand-mixing method can introduce a porosity of 7% or higher. It is confirmed that excessive
mixing can lead to increased porosity. By decreasing the number of beats and waiting for a
short duration after wetting the powder component with the monomer the porosity of ce‐
ment can be reduced to approximately 5%. Centrifugation was later introduced as a method
to eliminate pores. In this method, the liquid and powder components are initially hand
mixed and then placed in a tube and subjected to centrifugation at a speed of 2300 to 4000
rpm for a duration of 0.5 to 3 minutes. With this method the total porosity decreases to 1%
or less, which is significantly lower than the porosity observed in hand mixing. It is obvious
that for centrifugation to be effective, the viscosity of the cement must be relatively low, al‐
lowing the air bubbles to flow to the surface of the cement under the centrifugal force. One
way to assist centrifugation is to chill the MMA monomer prior to mixing. One potential dis‐
advantage of the centrifugation mixing technique is that it can lead to an inhomogeneous
distribution of radiopacifier particles in the centrifuged cement, due to the difference in den‐
sity of radiopacifier particles and PMMA and MMA monomer. The third type of mixing
technique is vacuum mixing, in which the two components of bone cements are placed in a
mixing bowl and are mixed after subjecting the bowl to vacuum conditions. The vacuum-
mixing devices have proven to substantially decrease porosity in cements to less than 1%
and consequently to increase their fatigue properties. Another major reason for using vac‐
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uum mixing is that MMA monomer is contained within the mixing bowl, which limits expo‐
sure to its vapors. Toxicology information obtained from materials safety data sheets
(MSDSs) show that MMA monomer is harmful if inhaled, swallowed, or absorbed through
the skin. [8, 14]
It must be noted that this reduction in the porosity of cement mantle with vacuum-mixing,
is not always the case. Messick et al found that vacuum-mixed cement does not result in
overall lower porosity of the cement, but the distribution of porosity may be different when
compared with that of hand-mixed cement.(Figure 5) It has also been demonstrated that
very high vacuum levels can be associated with the presence of cracks in the cement.[15]
Figure 5. Representative sections illustrating the distribution of porosity for A) hand- and B) vacuum-mixed cement.
7. Mechanical and physical properties
7.1. Static mechanical properties (Table 2)
The main function of acrylic bone cement is the stable fixation of endoprostheses. The ce‐
ment must endure considerable stresses, thus, sufficient strength is one of the most impor‐
tant demands to achieve a stable fixation and to guarantee long-term stability of the implant.
The cement layer has the effect of an elastic buffer between prosthesis and bone. Because of
its close adaptation to bone and its viscoelastic properties, it can reduce the stress concentra‐
tions at the interface with the bone. In the end, transferring load from the prosthesis to the
bone as efficiently as possible also is decisive for the long-term stability of the implant. The
mechanism of loading is especially complex for hip arthroplasty; therefore, it is difficult to
define what sufficient strength actually means. The total load affecting bone cement is a
mixture of compressive loading combined with bending, tension, shear, and torsion. It has
been extremely difficult to simulate this complex situation in the laboratory. Two mechani‐
cal tests have been introduced into ISO 5833, the relevant standard for testing acrylic bone
cements. These tests are the compression and the four-point bending test for the determina‐
tion of the compressive strength, the bending strength and the bending modulus (modulus
of elasticity or Young’s modulus), respectively. The standard ASTM F 451 includes the com‐
pression test only. Generally there are two different fundamental measuring principles to
The Acrylic Bone Cement in Arthroplasty
http://dx.doi.org/10.5772/53252
115
determine mechanical properties of bone cements: applying static (also called quasistatic)
stresses and dynamic stresses. Static tests are destructive tests with a uniaxial single loading,
increasing until failure, in contrast to dynamic tests that involve a cyclic loading.[16]
The compression test according to the standards ISO 5833 and ASTM F 451 is a static meth‐
od in which the compressive strength is defined as the maximum stress that a material can
withstand before failure in compression. The test is executed with a universal testing ma‐
chine equipped to record load versus crosshead displacement. The minimum requirement
for the compressive strength is 70 MPa according to the standards. All commercial antibiotic
and plain bone cements meet this requirement. Between both cement types, no significant
differences in compressive strength are observable.[10]
The second mechanical test according to ISO 5833 is the four-point bending test, also per‐
formed with a  universal  testing machine.  According to  ISO 5833 the minimum require‐
ment for  the bending strength is  50 MPa and for  the bending modulus it  is  1800 MPa,
respectively. Again, all commercial cements clearly fulfill  the requirements. The addition
of  antibiotics  reduces  the  bending  strength,  but  the  differences  between  antibiotic  and
plain cement are not always statistically significant. The bending modulus represents the
ratio of stress to corresponding strain of the material within the elastic range characteriz‐
ing the relative stiffness of the material. Stiff materials have a high modulus, eg, glass and
ceramics; ductile materials like rubber have a low modulus. Within the elastic range the
stress and strain are directly proportional following Hooke’s Law, and if  the load is  re‐
leased, the material regains its initial dimensions. The elastic range is limited by a stress
limit,  the so-called ‘‘proportional  limit’’  at  which the physical  properties of  the material
actually change and the material  might not recover its  initial  shape after releasing load.
As already mentioned the cement acts as a mechanical buffer. For this purpose the modu‐
lus of elasticity of bone cement has to be lower than the moduli of the metallic prosthesis
and  the  bone.  The  modulus  must  not  decrease  to  below  a  minimum  value,  however;
therefore,  a lower limit  for the modulus is  established in ISO 5833.  The modulus varies
with temperature, which means the higher the temperature, the lower the modulus. Test‐
ing bone cement at 23OC is not a really convenient way to get meaningful results for the
application  in  the  human body.  The  mechanical  performance  of  bone  cements  is  influ‐
enced by various parameters, such as composition of the cement, porosity, and prepara‐
tion of the cement. The addition of radiopacifier and antibiotics to a bone cement slightly
decreases the mechanical strength. These additives are necessary to get radiograph opaci‐
ty  and  antibiotic  protection  of  the  implant,  which  are  important  attributes  of  bone  ce‐
ments. Despite these additives, the resulting cements easily meet the requirements. [16,17]
Although bone cement has a high compressive strength, it is susceptible to fracture that
might result from tensile loading. Tensile tests therefore are performed according to ISO
527-1 or ASTM D 638. These standards describe a static test method applicable for all poly‐
mer materials. The uniaxial tensile test is executed with flat tapered specimens. The ultimate
tensile strength is defined as the maximum stress that a material can withstand before fail‐
ure in tension. The tensile strength is approximately 50 –60 MPa and there are no significant
differences between the tested materials. Again, the addition of antibiotics seems to reduce
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the tensile strength, but the differences between antibiotic and plain cement are not statisti‐
cally significant. [18]
The compressive strength of bone cement is higher than the flexural strength and that is
higher than the tensile strength. This descending order is found in all polymer materials.
That means tensile loading may be a higher risk factor for failure than compressive loading.
In vivo, simple tensile loading, however, does not play an important part in reality; complex
combinations of different loading types are more relevant. From a physical point of view,
bending is a mixture of compressive and tensile loading; therefore, the bending test actually
is a realistic test. [17]
One further static test applied with bone cements is the shear strength test according to
ASTM D732. This mechanical parameter is important because debonding of the stem–ce‐
ment interface has been implicated in the initiation of failure of cemented femoral stems.
The interface static shear strength is influenced by surface roughness, cement type, and po‐
rosity. Surface finish has the greatest effect on the interface strength. Increasing the surface
roughness increases the interface shear strength. Increasing the surface roughness to greater
than a certain value, however, has no additional affect. Cement type and porosity have a mi‐
nor influence on the static interface strength. [19]
Furthermore, there are methods to determine fracture properties, such as fracture toughness
(ASTM E399 and ISO 13,586) and impact strength (ISO 179/ISO 180/DIN 53,435). There is a
correlation between the two methods. For a given specimen configuration, g-irradiation pro‐
duced a statistically significant decrease in fracture toughness because of the concomitant
depreciation in molecular weight. Impact strength is a measure of the energy required to
cause a material to fracture when struck by a sudden blow. The addition of radiopacifier
and antibiotics together with pores in the cement might have a negative effect on the impact
strength. [20]
7.2. Water uptake and glass transition
When considering the mechanical tests described previously, one fact should be taken into
account: most of the tests are executed with dry specimens at room temperature. The cement
has to perform its task in the human body, however, in contact with body fluid and at a tem‐
perature of 37oC. Mechanical properties of polymers vary relative to their temperature and
water uptake. The absorption of water results in a lower modulus of elasticity and in a less
stiff material. The decreasing stiffness may even be advantageous for fracture resistance and
long-term stability of the implant. The water uptake of commercial bone cements is approxi‐
mately 1%–2% for plain bone cements and slightly higher for antibiotic bone cements. There
is high initial water uptake during the first days of incubation at 37oC. The bone cements are
completely water-saturated 4–8 weeks after incubation. The glass transition temperature is a
physical parameter defining the softening range of a material. Softening means a transition
from a hard and rigid glassy state with a high modulus to a soft rubbery state with a low
modulus by heating the polymer. If the material for anchoring endoprosthesis is in the rub‐
bery state, there would be a high risk for subsidence of the femoral stem and no stable fixa‐
tion of the implant would be possible. Bone cements therefore can be used only for fixation
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of endoprostheses at temperatures less than their glass transition temperature in the glassy
state. The glass transition temperatures of acrylic bone cements in a dry state range from
80o–100oC. These are high temperatures compared with the temperature of the human body.
The water absorption of the cement, however, results in a reduction in glass transition tem‐
perature of approximately 20o–30oC after 8 weeks of incubation in water. The glass transi‐
tion temperatures of water-saturated bone cements are approximately 60o–70oC. The
addition of antibiotics does not lower the glass transition significantly. Considering the pro‐
nounced difference between the glass transition temperature and the temperature of the hu‐
man body, the risk for sinking of the implant caused by creep seems to be very low.[16]
Property Value range (MPa)
Ultimate tensile strength 36 to 47
Ultimate compressive strength 80 to 94
Bending strength (4 point configuration) 67 to 72
Shear strength 50 to 69
Mean fracture toughness (Kic)** 1.52 to 2.02 (MPa√m)
*Simplex P, Palacos R, CMW1
**Kic, mean fracture toughness of brittle materials
Table 2. Mechanical properties of three cement brands*
7.3. Creep behavior
Polymers such as PMMA bone cements exhibit a combination of elastic and viscous behav‐
ior called viscoelasticity. When a polymer is subjected to a constant load, the resulting defor‐
mation can be divided into two parts: the immediate elastic deformation and the time-
dependent, continuous deformation. The immediate elastic deformation happens
instantaneously by applying load. It is a recoverable deformation essentially independent of
time. Following this rapid deformation there is a delayed continuous deformation resulting
from stress. One part of this deformation is recoverable in time after releasing load. This part
is called delayed elastic deformation or primary creep. The second part of this continuous
deformation is a non-recoverable permanent deformation called secondary creep.[21]
Different test methods are described in the standard ASTM D 2990 to measure creep. The
specimen is loaded by tensile, compressive, or flexural stress. In each method the change in
length of the specimen is measured and divided by the original length for the calculation of
creep. All plastic materials including acrylic bone cement creep to a certain extent. The de‐
gree of creep depends on several factors, such as composition of the material, temperature,
load, and load duration. Delayed injection time of acrylic bone cement increased creep com‐
pared with bone cement prepared according to standard injection procedures. Creep there‐
fore depends not only on the material properties, but also on the cement handling by the
surgeon.[22] It has been proposed that creep of acrylic bone cement may contribute to loos‐
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ening of cemented total joint replacements. The long-term prosthetic subsidence rates
caused by creep of acrylic cement, however, are small. On the other hand, cement creep re‐
laxes cement stresses and creates a more favorable stress distribution at the interfaces. [3, 16]
7.4. Fatigue behavior
To ensure survival of the cement in the human body, the bone cement must be able to with‐
stand the varying loads it endures. The fatigue properties of the cement thus are of particular
significance, and they may determine when a correctly used cement will fail or not. Many stud‐
ies have dealt with this topic, measuring fatigue properties in different ways. Today three dif‐
ferent standard testing procedures are used to characterize the fatigue behavior:
• Four-point bending arrangement recommended by ISO 5833 standard
• Uniaxial pure tensile test with flat tapered specimens according to ISO 527
• Uniaxial compression–tension test with cylindrical tapered specimens according to ASTM
F2118
• The first method is equivalent to the bending test method according to ISO 5833.
7.5. Fatigue testing
Fatigue testing is a dynamic test and is executed with a sinusoidal cyclic loading under
stress control. The tests are continued until failure or until run-out. The run-out limit is a
predetermined number of cycles at which the testing on a specimen is stopped, eg, 5 million
or 10 million cycles. The second method is equivalent to tensile testing according to ISO 527.
Again, the test run is performed with a sinusoidal cyclic loading under stress control until
failure or until run-out. The third method is according to ASTM F2118. The specimens are
subjected to fully reversed compressive and tensile loading in a sinusoidal cyclic manner.
Again, the tests are continued until failure or until the run-out limit is reached. Most fatigue
tests run at a specified frequency, eg, 5 Hz, in buffered saline solutions at 37oC.[16]
For tension–compression, the preliminary results exhibit a steeper decrease that might be
caused by a possibly stronger deterioration from the additional compressive loading. The
materials behave in a similar way under bending and uniaxial tension. The simplest test
configuration is the standardized four-point bending test according to ISO 5833. Additional‐
ly the preparation of the specimens for the tension–compression is much more complex than
the preparation of specimens for the bending test. For these two reasons the four-point
bending is the preferred method for fatigue testing. The environmental conditions in which
these experiments are conducted have a considerable influence on the fatigue life. Bone ce‐
ments have different fatigue behavior if tested dry or in aqueous solution. The tests in air at
room temperature result in a stress-number of cycles-curve (S-N-curve) of considerably
higher slope. To simulate the body environment, tests should be performed in an appropri‐
ate liquid, such as simulated body fluid or Ringer’s solution. The results of tests in air at lab‐
oratory temperature should be rated carefully.
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Furthermore, the sterilization process of the polymer powder has an influence on fatigue be‐
havior of acrylic bone cements. Sterilization by γ-irradiation or b-irradiation significantly
lowers the molecular weight of the polymer powder and the resulting cured bone cement,
whereas sterilization by ethylene oxide has no influence on the molecular weight of the pol‐
ymer. Bone cement with high molecular weight has a better fatigue performance than a ce‐
ment with low molecular weight.[17]
Porosity is a major cause of reduced fatigue life of bone cement. Pores or other inclusions
serve to concentrate stress in the material and often initiate fatigue cracks within the bone
cement. These cracks ultimately lead to failure. The sources of porosity are air initially sur‐
rounding the powder, which is trapped during wetting of the powder, air trapping in the
cement during mixing, and air trapping in the cement during transfer from mixing container
to application device. Hand-mixed bone cement in an open bowl has a significantly higher
number of pores than bone cement mixed in a vacuum mixing system. Modern cement mix‐
ing systems reduce cement porosity and enhance cement strength by eliminating the chan‐
ces of air entrapment in the cement.[23]
8. Antibiotics
Buchholz and Engelbrecht were the first to add gentamicin antibiotic to a bone cement.[3]
Initially the antibiotic was added by hand, and subsequently during manufacture, making
antibiotic-loaded acrylic cement widely available as part of antimicrobial prophylaxis in pri‐
mary arthroplasty. It was shown later, that oxacillin, cefazolin, and gentamicin are all stable
in PMMA bone cement and were released in active form. The largest release of antibiotics
occurred in the first 24 hours, but high bactericidal concentrations of the antibiotics were
measured in the periprosthetic bone for up to 21 days after implantation. A small amount of
antibiotic elution is observed even after 5 years. Bone cement without any antibiotics had no
bacteriostatic effect on Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa or‐
ganisms. [24]
Bone cements can function as a matrix for the local application of antibiotics. Because of the
high local concentration of an antibiotic in the surroundings of the implant, the use of bone
cements has great advantages compared with a systemic antibiotic therapy. The artificial im‐
plant is especially sensitive to bacterial contamination on its surface, because the microor‐
ganisms may proliferate there almost unhampered by the immune defense of the body. As
the bacteria rapidly generate a protective mucus layer and go to an inactive state with low
sensitivity to antibiotics, a local antibiotic treatment is important. The pharmacokinetics of
the antibiotic release from the matrix is of clinical importance. The local antibiotic concentra‐
tions reached must be clearly greater than the minimal inhibitory concentration and the
minimal bactericidal concentration for the organisms. Not all antibiotics are suitable for use
in bone cements. To avoid the development of resistant strains, a high initial level with a
subsequent controlled release for days or weeks is important. The following bacteriologic
and physical and chemical factors should be considered in the choice of an antibiotic:
Arthroplasty - Update120
1. Broad antibacterial spectra, including gram-positive and gram-negative organisms
2. Good bactericidal effect in low concentrations
3. Low incidence of primary resistant germs
4. Low rate of development of resistances
5. Low protein bonding
6. Low allergic potential
7. Little effect on bone cement mechanics
8. Chemical and thermal stability
9. Good solubility in water
10. Good release from bone cement
Based on these requirements and release tests, gentamicin has become the favorite antibiotic
for bone cements since the early 1970s. Gentamicin is the most common additive because it
has, amongst other features, a good spectrum of concentration-dependent bactericidal activ‐
ity, thermal stability and high water solubility. [7]
Antibiotics are added in the form of powder, which is unable to diffuse through a hard,
glassy polymer. So the mechanism of elution of the antibiotics is believed to be closely relat‐
ed to water-absorbing properties of the cement with respect to time and distance from the
surface of the cement. The diffusion rate of the antibiotics depends on several factors, such
as the chemical composition of the cement, the surface area at the cement-bone interface,
and cement handling. For example, Palacos cement containing prepolymerized beads of
P(MMA-co-MA) were shown to elute gentamicin at more rapidly than Simplex containing
prepolymerized beads of P(MMA-co-S). In addition, vacuum mixing, which decreases the
porosity in bone cement, can also alter the kinetics of the elution of antibiotics and was
shown to decrease their rate of elution by 50%.[25]
Penner et al investigated the release of vancomycin and tobramycin from bone cement sepa‐
rately or combined in nonvacuum preparations. They observed that the combined use of the
2 antibiotics led to an increased elution of both from cement. Baleani et al also showed that
the presence of meropenem broadened the antibacterial spectrum and enhanced the elution
of vancomycin from cement. [26]
Since powder gentamicin is a costly antibiotic and is not available for hand-mixing with
bone cement in operating rooms, many researchers have tried to add liquid gentamicin to
bone cements. The liquid gentamicin, a much less costly antibiotic (1/20 the price of tobra‐
mycin) with a broad antimicrobial spectrum, is widely available throughout the world, but
there is always a fear of deteriorating the mechanical properties of the bone cement by add‐
ing liquid gentamicin. Hsieh PH et al investigated the use of liquid gentamicin, alone and in
combination with vancomycin, incorporated into acrylic bone cement as a potential treat‐
ment of complex orthopedic infections. They assessed the cement specimens loaded with
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480 mg of liquid gentamicin, 4 g of powdered vancomycin, or both antibiotics for elution
characteristics, bioactivity, compressive strength, and porosity. Vancomycin elution was en‐
hanced by 146% with the addition of gentamicin liquid, and gentamicin elution was en‐
hanced by 45% when combined with vancomycin. Bioassay confirmed the bactericidal
activity of the released antibiotics. Adding liquid gentamicin increased porosity, whereas
adding vancomycin did not. Compressive strength decreased by 13%, 37%, and 45% in
specimens containing vancomycin, liquid gentamicin, and both antibiotics, respectively.(Ta‐
ble 3) Despite inferior mechanical properties, the temporary nature of cement beads and
spacers makes the liquid gentamicin–vancomycin mixture a potentially more cost-effective
regimen in bone cement to treat musculoskeletal infections. [27]
Vancomycin Gentamicin Both antibiotics
Porosity* (%) 5.8 ± 2.6 16.8 ± 1.9 22.4 ± 3.4
Compressive strength (MPa) 79.69 ± 6.2 57.99 ± 1.5 50.32 ± 4.9
*Porosity as a percentage of the total area.
Table 3. Porosity and ultimate compressive strength of the specimens
Other antibiotics with suitable spectra against orthopaedic infecting organisms, such as cefa‐
zolin, ciprofloxacin, linezolid, levofloxacin and rifampin, have been tested according to their
elution and bactericidal activities and have been shown that all these antibiotics may be suit‐
able for incorporation into polymethylmethacrylate for management of orthopaedic infec‐
tions.[28] (Table 4)
But it worth noting that all antibiotics are not suitable for adding to bone cements. Goss et al
have shown that amphotericin B does not elute from polymethylmethacrylate bone cement.
However, addition of this antifungal increases the mechanical strength by forming covalent
crosslinks in the PMMA matrix, imparting better mechanical properties. [29]
Antibiotics premixed into the cement by the manufacturer can be advantageous since the
addition of antibiotic powder manually can lead to agglomeration and a decrease in the me‐
chanical strength of the cement. Antibiotics are added to cement in the powdered form since
it was demonstrated that the addition of liquid antibiotics resulted in a decrease in mechani‐
cal strength due to interference with the early stages of polymerization of the MMA mono‐
mer. The amount of antibiotic powder required for a therapeutic level of elution is
approximately 0.5 to 2 g in a standard 40-g package of prepolymerized PMMA powder.
Note that antibiotic powder, like radiopacifiers and pores, also results in defects or flaws in
bone cement. The flexural strength of antibiotic-containing cement was shown to be lower
than that of cement without antibiotics, and the toughness of antibiotic-containing cement
decreased further with excessive amounts of antibiotics. A likely reason for this is that ex‐
cess amounts of undissolved antibiotics agglomerate into aggregates exceeding the critical
flaw size for PMMA. However, doses of 2 g of well-dispersed antibiotic powder may not
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have any adverse effect on the mechanical properties of bone cement if the size of the inclu‐
sions remains below the critical flaw size for PMMA.
Antimicrobial Amount (%) AUC (µg/mL/h)
Peak
concentration
(µg/mL)
Time no longer
detectable (h)
Percent in the bead
before elution
Cefazolin 2.5 18 ± 3 15 ± 2 2 ± 0 56 ± 2
7.5 162 ± 33 62 ± 23 10 ± 1 42 ± 4
15 792 ± 47 147 ± 22 26 ± 1 54 ± 5
Ciprofloxacin 2.5 23 ± 5 5 ± 0 45 ± 3 36 ± 3
7.5 112 ± 3 15 ± 1 45 ± 5 36 ± 7
15 307 ± 10 54 ± 3 48 ± 0 31 ± 3
Gatifloxacin 2.5 157 ± 34 15 ± 2 48 ± 0 45 ± 2
7.5 190 ± 65 19 ± 1 48 ± 0 47 ± 4
15 499 ± 51 51 ± 3 48 ± 0 50 ± 3
Levofloxacin 2.5 33 ± 4 7 ± 1 48 ± 0 28 ± 3
7.5 123 ± 7 26 ± 3 48 ± 0 23 ± 3
15 291 ± 59 52 ± 10 48 ± 0 24 ± 3
Linezolid 2.5 Not detected <5 0 ± 0 96 ± 5
7.5 213 ± 53 43 ± 4 12 ± 4 88 ±4
15 224 ± 155 64 ± 47 22 ± 2 84 ± 4
Rifampin 2.5 5 ± 2 4 ± 1 2 ± 1 21 ± 1
7.5 147 ± 15 15 ± 2 37 ± 1 27 ± 4
15 409 ± 46 31 ± 11 48 ± 0 24 ±1
AUC: area under the curve
Table 4. Parameters of release from PMMA for studied antimicrobials
8.1. Costs of antibiotic-loaded bone cement
Currently the increased acquisition cost of commercially available antibiotic-loaded bone-ce‐
ment products is considerable. Compared with the cost of plain bone-cement products, the
cost of equivalent antibiotic-loaded bone-cement products is increased anywhere from $284
to $349 (United States dollars) per 40-g packet. If the historical 11% usage of antibiotic-load‐
ed bone cement increased to 50% of the estimated 500,000 primary total joint arthroplasties
performed annually in the United States, and if two packets of cement (at a $300 increased
cost per packet) were used for each joint replacement, the increase in overall health-care
costs would be $117,000,000 for the 195,000 additional cases. This estimated increased
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health-care cost must be balanced with the potential cost savings associated with a realized
reduction in the rate of infection associated with routine use of antibiotic-loaded bone ce‐
ment for prophylaxis in primary total joint replacement. At an approximately $50,000 cost
for the treatment of an infection at the site of a total joint replacement, there would have to
be 2340 fewer infected patients among the additional 195,000 patients for the routine use of
antibiotic-loaded bone cement to be fiscally neutral. With a rather high estimated infection
rate of 1.5%, a deep postoperative infection could be expected to develop in 2925 of 195,000
patients. In other words, the rate of deep periprosthetic infection would need to be reduced
from this 1.5% to 0.3% to recover the costs associated with the routine use of commercially
available low-dose antibiotic-loaded bone cement in primary total joint arthroplasty. More‐
over, while the estimated costs for the treatment of an infection at the site of a total joint ar‐
throplasty do not account for morbidity and mortality associated with the treatment
required, the increased costs associated with the treatment of more drug-resistant organisms
are unknown. [30]
8.2. Choice of antibiotic in antibiotic-loaded bone cement used prophylactically
The aminoglycoside antibiotics were originally selected for use in antibiotic-loaded bone ce‐
ment because of their broad bacterial coverage and their low allergy profile. Because the lev‐
el of gentamicin or tobramycin in the joint is often ten times greater than safe blood levels,
the efficacy of those drugs is excellent unless the organism has a specific resistance to them.
Gentamicin and tobramycin are also the only antibiotics currently available in commercially
premixed low-dose antibiotic-loaded bone-cement preparations. As mentioned above, how‐
ever, low doses of other types of antibiotics, including several of the cephalosporins, have
been hand-mixed into bone-cement preparations, and those preparations have had good
success in prophylactic applications. Allergic reactions have not been reported, to our
knowledge, but it is prudent for the surgeon to consider the individual patient’s allergy his‐
tory before selecting the antibiotic for antibiotic-loaded bone cement. There has been consid‐
erable research on the primary bacterial contaminants in total joint surgery.
Al-Maiyah et al. took 627 blood-agar impressions of the gloved hands of surgical personnel
during the performance of fifty total hip arthroplasties in England. Bacteria grew on culture
of fifty-seven impressions (9%); 69% were coagulase-negative staphylococci, 12% were Mi‐
crococcus, 9% were diphtheroids, and 6% were Staphylococcus aureus. Of the coagulase-nega‐
tive staphylococci, only 52% were sensitive to cefuroxime. In contrast, Ridgeway et al. found
Staphylococcus aureus in 50% of the surgical site infections (both superficial and deep) in their
multiple-hospital study in England. More than half of the Staphylococcus aureus isolates were
methicillin-resistant. Thus, it appears that staphylococcal species are the primary bacteria to‐
ward which antibiotic-loaded bone cement would be directed. The currently available com‐
mercial gentamicin or tobramycin-loaded bone cements provide sufficient elution
concentrations to be bactericidal even against methicillin-resistant organisms. Vancomycin
may also be added to bone cement, but it has a lower efficacy than gentamicin or tobramy‐
cin at these concentrations. The use of vancomycin should be considered in revisions follow‐
ing primary arthroplasties in which gentamicin or tobramycin-loaded bone cement had
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been used because of the prevalence of gentamicin resistance in association with such revi‐
sions. Cephalosporins may also be considered for antibiotic-loaded bone cement that is to be
used prophylactically but may not be effective against methicillin-resistant organisms.[30]
9. Adverse effects of bone cement
9.1. Cardiopulmonary complications
Cardiopulmonary complications associated with PMMA have been reported in conjunction
with hip arthroplasty and VA. Prior studies have postulated that PMMA-associated hypo‐
xia, hypotension, and death may occur as a result of the toxic effects of monomer or anaphy‐
laxis. Other literature indicates that the application of PMMA may lead to embolization of
marrow debris and neurogenic reflex, thus adversely affecting cardiopulmonary function.
Pulmonary infarction and death have been reported as a result of embolization of PMMA
that was injected in liquid state following VA. [2]
9.2. Hypersensitivity to components of methylmethacrylate, especially benzoyl peroxide
A small but significant proportion of cemented total knee arthroplasties develop early asep‐
tic loosening. Polyethylene debris is unlikely to be the cause in the small subgroup that ex‐
periences early loosening. Allergy to polymethylmethacrylate bone cement or its
constituents has been reported in dentistry, dermatology, and joint arthroplasty. Although
allergy to polymethylmethacrylate bone cement or its constituents is unusual, the possibility
of a systemic inflammatory response and consequent pain and loosening must be consid‐
ered. Benzoyl peroxide is an essential component of bone cement. Direct evidence for aller‐
gic reactions to benzoyl peroxide has been reported in dental and dermatological literature.
The currently accepted model for this delayed hypersensitivity is that a hapten such as ben‐
zoyl peroxide conjugates with a body protein, which creates a neoantigen capable of stimu‐
lating an immune response. This hypersensitivity places the patient at risk of developing
insidious pain, a systemic inflammatory response, and possibly aseptic loosening. After re‐
vision to uncemented femoral and tibial components, the patient’s symptoms vastly im‐
proved.[31]
9.3. Presence of components of methylmethacrylate in serum and breast milk
Singh et al. reported dose-related teratogenic and fetal toxic effects of methacrylic acid ad‐
ministered via the intraperitoneal route in rats. McLaughlin et al. exposed pregnant mice to
very high vapor concentrations of methacrylic acid of 1330 parts per million for two consec‐
utive hours, twice daily. The mice demonstrated no evidence of fetal toxicity or teratogenic
effects; in fact, there was a slight increase in fetal weight with methacrylic acid exposure.
The only published study that has addressed methacrylic acid exposure during lactation in‐
volved a patient undergoing arthroplasty, not operating room personnel who were exposed
to methacrylic acid vapors. In that study, Hersh et al. found undetectable levels of polyme‐
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thylmethacrylate in breast milk that was collected thirty-six hours after hybrid total hip ar‐
throplasty in a twenty-nine-year-old woman who was five months postpartum. Linehan et
al. showed undetectable levels of methacrylic acid (at the 0.5-part-per-million level) in the
serum and breast milk of two lactating surgeons who had been exposed to typical operating
room conditions without the use of personal exhaust systems. [32]
10. Composite bone cements
PMMA-based bone cement has a high modulus but low toughness compared with ductile
polymers. In order to address the lack of fracture toughness and fatigue strength, many in‐
vestigators who have developed new composite PMMA cements use the concept of fiber re‐
inforcement and incorporate a low-volume fraction of chopped fibers of approximately 1%
to 2%.[33] Several types of fibers, such as fibers made of carbon, polyethylene terephthalate,
oriented PMMA, ultra high molecular weight polyethylene, titanium, aramid, Kevlar,
graphite, steel, and zirconia fibers with and without acrylic coating have been used to rein‐
force PMMA-based bone cement.[33-6] While these composites have displayed improved fa‐
tigue failure properties, biocompatibility concerns and complications of processing have
prevented their implementation in the manufacture of PMMA bone cement.
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